Australia markets closed

Aptinyx Inc. (APTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.2848+0.0033 (+1.17%)
At close: 01:00PM EST
Full screen
Loading interactive chart…
  • Business Wire

    Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience

    EVANSTON, Ill., November 10, 2022--Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster presentations at the 52nd Annual Meeting of the Society for Neuroscience being held November 12-16, 2022 in San Diego, CA. The presentations include preclinical data supporting the development of NYX-783, an NMDA receptor positive allosteric modulator in post-traumatic

  • Business Wire

    Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

    EVANSTON, Ill., November 08, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.

  • Business Wire

    Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant

    EVANSTON, Ill., November 03, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the finalization of a $5.6 million grant under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, supporting the development of NYX-783 for the treatment of opioid use disorder (OUD). NYX-783 is an NMDA receptor positive allosteric modulator also in P